title: Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents.
abstract: Catalepsy was observed in the rat following intrastriatal injections of the dopamine antagonists sulpiride or fluphenazine and after subcutaneous administration of fluphenazine. The neuroleptic-induced catalepsy was reversed by the classical anti-parkinsonian agent L-DOPA and by agents that function through dopamine systems such as d- and methamphetamine and the direct D2 receptor agonist quinpirole. The D1 agonist SKF 38393, and the D1/D2 agonist apomorphine, were ineffective in this model. These results support limited use of the rat catalepsy model for the screening of potential anti-parkinsonian compounds and indicate that this procedure can provide valuable information concerning striatal dopamine function.
authors.affiliation: Glaxo Group Research Ltd., Neuropharmacology Department, Ware, Hertfordshire, United Kingdom.
authors.forename: P J
authors.initials: PJ
authors.lastname: Elliott
authors.forename: S P
authors.initials: SP
authors.lastname: Close
authors.forename: D M
authors.initials: DM
authors.lastname: Walsh
authors.forename: A G
authors.initials: AG
authors.lastname: Hayes
authors.forename: A S
authors.initials: AS
authors.lastname: Marriott
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D002375:Catalepsy / Q000139:chemically induced* / Q000503:physiopathology; D004195:Disease Models, Animal; D004298:Dopamine / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D005476:Fluphenazine / Q000494:pharmacology*; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008694:Methamphetamine / Q000627:therapeutic use; D008845:Microinjections; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D051381:Rats; D013469:Sulpiride / Q000494:pharmacology*
chemical_list: D014150:Antipsychotic Agents; D008694:Methamphetamine; D007980:Levodopa; D013469:Sulpiride; D005476:Fluphenazine; D004298:Dopamine